Merrick Blair, Sergaki Chrysi, Edwards Lindsey, Moyes David L, Kertanegara Michael, Prossomariti Désirée, Shawcross Debbie L, Goldenberg Simon D
Centre for Clinical Infection and Diagnostics Research, Guy's and St Thomas' NHS Foundation Trust, King's College, London SE1 7EH, UK.
Diagnostics R&D, Medicines and Healthcare Products Regulatory Agency (MHRA), Potters Bar EN6 3QG, UK.
Infect Dis Rep. 2023 May 9;15(3):238-254. doi: 10.3390/idr15030025.
Antimicrobial resistance (AMR) is one of the greatest challenges facing humanity, causing a substantial burden to the global healthcare system. AMR in Gram-negative organisms is particularly concerning due to a dramatic rise in infections caused by extended-spectrum beta-lactamase and carbapenemase-producing Enterobacterales (ESBL and CPE). These pathogens have limited treatment options and are associated with poor clinical outcomes, including high mortality rates. The microbiota of the gastrointestinal tract acts as a major reservoir of antibiotic resistance genes (the resistome), and the environment facilitates intra and inter-species transfer of mobile genetic elements carrying these resistance genes. As colonisation often precedes infection, strategies to manipulate the resistome to limit endogenous infections with AMR organisms, as well as prevent transmission to others, is a worthwhile pursuit. This narrative review presents existing evidence on how manipulation of the gut microbiota can be exploited to therapeutically restore colonisation resistance using a number of methods, including diet, probiotics, bacteriophages and faecal microbiota transplantation (FMT).
Front Microbiol. 2020-2-11
NPJ Antimicrob Resist. 2025-6-19
Front Microbiol. 2025-5-20
Front Microbiol. 2023-11-23
Microorganisms. 2023-7-27
Front Pharmacol. 2023-1-24
Nat Rev Microbiol. 2023-6
Front Bioeng Biotechnol. 2022-9-16
J Control Release. 2022-10
Ann Med Surg (Lond). 2022-7-31
Nat Microbiol. 2022-6